Subanalysis of the OZIRKA study: efficacy of Ozalex (rosuvastatin) in patients with diabetes mellitus
Keywords:diabetes mellitus, arterial hypertension, dyslipidemia, rosuvastatin
Background. Diabetes mellitus (DM) remains one of the most important cardiovascular risk factors significantly worsening the prognosis in patients with hypertension and dyslipidemia. The leading role among drugs for the treatment of such patients belongs to statins with their powerful influence on the development and progression of atherosclerosis and its complications. We used the OZIRKA study database and performed additional subanalysis to study the effects of rosuvastatin in patients with diabetes and dyslipidemia. Purpose: to study the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia and DM. Materials and methods. It was a prospective open population study. The recruitment of patients was conducted from March to December 2019. The analysis of the study data was conducted from June to November 2020. Results. A total of 20,000 patients from all over Ukraine were included in the study. The full follow-up period was completed by 18,100 patients, of whom 17,530 had all the necessary data, they were included in the final analysis. The mean follow-up period was 2.2 months. Approximately 13 % of patients included in the study had DM type 2. We observed a significant reduction in total cholesterol, low-density lipoprotein (LDL) and triglyceride levels in patients with diabetes. In addition, there was a tendency to an increase in the level of high-density lipoproteins in this group of patients. In general, it can be noted that there was a significant improvement in lipid profile in patients with diabetes: the level of total cholesterol decreased by 28 %, LDL cholesterol — by 34 %, triglycerides — by 24 %. Administration of rosuvastatin did not impair glucose control in any way in the group of patients with DM; moreover, even in the group of people without DM, there was no negative effect of rosuvastatin on fasting glucose level. Conclusions. In general, we can recommend Ozalex in a dose of 10 to 20 mg as an optimal start of statin therapy at the stage of primary care for patients with DM.
Nelson A.J., Rochelau S.K., Nicholls S.J. Managing Dyslipidemia in Type 2 Diabetes. Endocrinol. Metab. Clin. 2018 Mar. 47(1). 153-173.
Park Z.H., Juska А., Dyakov D., Patel R.V. Statin-associated incident diabetes: a literature review. Consult Pharm. 2014. 29(5). 317-34.
Simsek S., Schalkwijk C.G., Wolffenbuttel B.Н.R. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes — the CORALL study. Diabet Med. 2012 May. 29(5). 628-31.
Ridker P.М., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11. 380(9841). 565-71.
Mach F., Baigent C., Catapano A.L et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020. 41(1). 111-188.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.